drug,target,pathway,n_ecdna_pos,n_ecdna_neg,mean_ic50_ecdna_pos,mean_ic50_ecdna_neg,selectivity_ratio,cohens_d,pvalue,significant
Dinaciclib,CDK1/2/5/9,Cell cycle,10,90,1.579757010553488,2.4903908007884685,1.5764391511805529,0.6260977130931215,0.030151894374929995,True
Palbociclib,CDK4/6,Cell cycle,10,90,1.9295195699128949,2.4903908007884685,1.2906792134276686,0.35099186855407044,0.15736447865902797,False
AZD7762,CHK1/CHK2,DNA damage,10,90,1.2933956469306787,2.4903908007884685,1.9254671273236044,0.9012035576321725,0.00643186093037553,True
Bortezomib,Proteasome,Proteostasis,10,90,1.745901505689839,2.4903908007884685,1.4264211312450112,0.4885447908235959,0.06991472681133218,False
Navitoclax,BCL2/BCL-XL/BCL-W,Apoptosis,10,90,1.9295195699128949,2.4903908007884685,1.2906792134276686,0.35099186855407044,0.15736447865902797,False
Gemcitabine,DNA synthesis,DNA replication,10,90,2.1324489145255625,2.4903908007884685,1.1678548469905747,0.21343894628454496,0.2258525715284327,False
